In Situ Crystallized Ceria‐Vesicle Nanohybrid Therapeutic for Effective Treatment of Inflammatory Intraocular Disease
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202402523 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Jiawei Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, P. R. China. Hauptthemen laut MEDLINE: Cerium, Extracellular Vesicles, Mesenchymal Stem Cells, Uveitis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Hospitals Authority's Ascent Program, Capital Health Development Scientific Research Project.
Abstract (Originalsprache)
Posterior uveitis is a leading cause of vision impairment and blindness globally due to its detrimental effects on the choroid and retina. The condition is worsened by oxidative stress, which heightens inflammation and perpetuates a cycle of damage that current treatments only temporarily relieve. To address this, a novel treatment involving the in situ crystallization of ultrasmall cerium oxide nanoparticles (≈3 nm) on mesenchymal stem cell (MSC) extracellular vesicles (EVs) for the management of primed mycobacterial uveitis (PMU) is developed. This nanohybrid leverages the individual and synergistic effects of its components for a comprehensive therapeutic approach. The cerium oxide nanoparticles act as a nanozyme to reduce inflammation and scavenge excessive reactive oxygen species (ROS), while the MSC EVs, with their biocompatibility, modulate inflammatory cell infiltration and alleviate tissue damage. This synergistic system offers a promising new treatment strategy for ocular diseases characterized by oxidative stress and inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, P. R. China.
ORCID-Profile: Jiawei Zhao, Yong Tao
Förderung
- National Natural Science Foundation of China
- Beijing Hospitals Authority's Ascent Program
- Capital Health Development Scientific Research Project
- Beijing Nova Program
- Chinese Institutes for Medical Research
- Excellent Young Talent Innovation Project
Zitieren
APA
Zhao, J., Wang, Y., Zhang, Y., Guo, X., Bao, H., & Tao, Y. (2025). In Situ Crystallized Ceria‐Vesicle Nanohybrid Therapeutic for Effective Treatment of Inflammatory Intraocular Disease. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402523
Vancouver
Zhao J, Wang Y, Zhang Y, Guo X, Bao H, Tao Y. In Situ Crystallized Ceria‐Vesicle Nanohybrid Therapeutic for Effective Treatment of Inflammatory Intraocular Disease. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202402523
BibTeX
@article{Zhao2025,
author = {Zhao, Jiawei and Wang, Yingjie and Zhang, Yiquan and Guo, Xinyu and Bao, Han and Tao, Yong},
title = {In Situ Crystallized Ceria‐Vesicle Nanohybrid Therapeutic for Effective Treatment of Inflammatory Intraocular Disease},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202402523}
}
EUVIMED